Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:VERA

Vera Therapeutics Q3 2026 Earnings Date & Estimates

Vera Therapeutics logo
$28.30 +0.31 (+1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$28.50 +0.20 (+0.71%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vera Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vera Therapeutics in Q3 2026

Vera Therapeutics is expected to post earnings of -$1.61 per share on revenue of $3.90 million. In the same quarter a year earlier Vera Therapeutics reported -$1.26 per share. Vera Therapeutics last reported on August 10, 2026, posting -$1.52 per share and beating the -$1.58 consensus estimate. Vera Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.61
Expected Revenue
$3.90 million
Prior-Year EPS
-$1.26

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.52 (Beat by +$0.06)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Vera Therapeutics Q3 2026 Earnings FAQ

Vera Therapeutics (NASDAQ:VERA) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Vera Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Vera Therapeutics to post earnings of -$1.61 per share for Q3 2026.

The consensus revenue estimate for Vera Therapeutics is $3.90 million for Q3 2026.

Vera Therapeutics Earnings Headlines

Wedbush Sticks to Their Hold Rating for Vera Therapeutics (VERA)
October 24 at 7:41 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VERA/pressreleases/8410132/wedbush-sticks-to-their-hold-rating-for-vera-therapeutics-vera/
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
October 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4956681-vera-therapeutics-inc-vera-discusses-final-efficacy-results-of-origin-phase-iii-trial-of
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
October 26 at 1:00 AM  |  Crypto 101 Media (Ad)
Vera's TRUTAKNA Shows Kidney Benefit In Final Phase 3 IgA Nephropathy Analysis
October 22, 2026  |  rttnews.comhttps://www.rttnews.com/3701923/vera-s-trutakna-shows-kidney-benefit-in-final-phase-3-iga-nephropathy-analysis.aspx
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the ...
October 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vera-therapeutics-announces-positive-origin-3-final-efficacy-analysis-of-trutakna-atacicept-vymj-in-iga-nephropathy-presented-at-asn-kidney-week-2026-and-published-in-the-new-england-journal-of-1036655088
Vera Therapeutics Announces ORIGIN 3 Final Analysis Shows TRUTAKNA Met All Prespecified Endpoints in IgA Nephropathy
October 22, 2026  |  quiverquant.comQ
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases. Vera’s development programs are intended to serve patients in the United States and international markets, subject to clinical results and regulatory approvals.

Founded in 2016 and headquartered in South San Francisco, California, Vera became a publicly traded company on the Nasdaq under the symbol VERA in 2021. The company is led by Marshall Fordyce, M.D., who serves as chief executive officer and has been involved in the development of therapies for immune-mediated diseases.

View Vera Therapeutics Profile
Earnings Tools